InnoCare Pharma’s Orelabrutinib Gains Approval for First-Line CLL/SLL Treatment in China

InnoCare Pharma Ltd. ( (HK:9969) ) has issued an update.

InnoCare Pharma Ltd. has announced that its core product, Orelabrutinib, has received approval from the China National Medical Products Administration for the first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). This approval marks a significant expansion of Orelabrutinib’s indications, which previously included treatments for relapsed and refractory CLL/SLL, mantle cell lymphoma, and marginal zone lymphoma. The inclusion of Orelabrutinib in the Chinese Society of Clinical Oncology’s guidelines as a Class I recommended therapy further strengthens its market position and potential impact on a broader patient population.

More about InnoCare Pharma Ltd.

InnoCare Pharma Ltd. is a pharmaceutical company focused on the development and commercialization of innovative therapies. The company specializes in treatments for cancer and autoimmune diseases, with a particular emphasis on Bruton Tyrosine Kinase (BTK) inhibitors.

YTD Price Performance: 71.90%

Average Trading Volume: 12,387,038

Technical Sentiment Signal: Sell

Current Market Cap: HK$15.74B

See more data about 9969 stock on TipRanks’ Stock Analysis page.